Beyond the Acute Effect: Pharmacokinetics, Temporal Stigma, and the Classification of Therapeutic Benzodiazepine Use

Abstract Benzodiazepines remain among the most widely prescribed medications for the treatment of anxiety disorders, insomnia, panic disorder, and related conditions. While their therapeutic benefits and adverse effects are well established, long-term therapeutic use is often assumed to imply persistent cognitive impairment. This article argues that such an inference may constitute a classification error when pharmacokinetic variables, pharmacodynamic tolerance, cognitive reserve, dosage, administration schedule, and clinical context are not adequately considered. Rather than denying the known risks associated with benzodiazepines, the paper distinguishes transient pharmacological effects from enduring cognitive conditions and examines how this distinction influences clinical interpretation and social stigma. Drawing upon pharmacokinetics, contemporary evidence on cognition and dementia, and epistemological analysis, the article proposes a more context-sensitive framework for evaluating therapeutic benzodiazepine use while reducing unjustified temporal stigmatization. The broader implications for medical reasoning and patient evaluation are also discussed.